The inhibition of upstream tyrosine kinases has ledto downstream abrogation of STAT-3 signaling with antitumor effects in multiplepreclinical models, including prostate cancer (Gu et al., 2014). This evidence concerns the gene STAT3 and Familial prostate cancer.